



NEWS RELEASE

Exact Sciences Obtains Exclusive License to Oncomethylome Sciences' DNA Methylation Biomarkers

Madison, Wis. and Liege, Belgium, July 27, 2010 – 7:30 EDT – Exact Sciences Corp. (Nasdaq: EXAS) and OncoMethylome Sciences S.A. (Euronext Brussels: ONCOB) today announced that they have entered into a license agreement under which Exact Sciences has obtained exclusive, worldwide rights to up to two OncoMethylome Sciences' DNA methylation biomarkers for use in stool-based detection of colorectal cancer. Exact Sciences has also gained non-exclusive access to part of OncoMethylome's platform technology. In return, OncoMethylome Sciences will receive milestone payments and royalties on net sales.

DNA methylation regulates gene expression, and multiple scientific studies have shown that methylation markers are clinically relevant markers for colorectal cancer. In cancers and pre-cancers, methylation biomarkers are typically present more frequently than individual DNA mutation biomarkers, and as a result, fewer methylation markers are required to detect most cancers and pre-cancers.

"We are delighted to be able to add new markers to our current test panel," said Kevin T. Conroy, president and chief executive of Exact Sciences. "Our team has developed a new approach to stool-DNA testing that uniquely includes multiple methylation markers in a single assay, and achieves exceptionally high sensitivity and specificity. The inclusion of these markers makes us even more confident about the likelihood of success with our upcoming validation study, the results of which we plan to discuss on October 29, 2010 at the American Association of Cancer Research (AACR) colorectal cancer meeting in Philadelphia. We also look forward to presenting preliminary performance data on the combination of methylation biomarkers in colorectal cancer and pre-cancer tissue tomorrow, July 28, 2010, at the American Association of Clinical Chemistry (AACC) annual meeting in Anaheim, Calif."

"We believe that the combination of our biomarkers and platform with the test panel of Exact Sciences holds great promise for the development of a very powerful detection tool for colorectal cancer," stated Jan Groen, president and chief executive officer of OncoMethylome Sciences. "Exact Sciences has made impressive progress in the development of their test panel, and this licensing agreement allows OncoMethylome to more rapidly and effectively capitalize on the value of its colon cancer program".

About OncoMethylome Sciences

OncoMethylome Sciences is a leading molecular diagnostics company that commercializes and develops cancer-screening tests to assist physicians in detecting and treating cancer early. The company's tests are based on proprietary gene methylation technology invented at Johns Hopkins University and are designed to help the physician accurately detect early stages of cancer development, predict a patient's response to drug therapy, and predict the likelihood of cancer recurrence. OncoMethylome Sciences collaborates with leading cancer research centers, such as Johns Hopkins, in Baltimore, MD, and has a number of commercial and collaborative partnerships with LabCorp, Schering-Plough, GlaxoSmithKline Biologicals, Roche, Millipore Corporation's BioScience Division, Merck Serono and Qiagen.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

For more information:

Oncomethylome Sciences Contact:

Dr. Jan Groen
President and CEO
+32 4.364.20.70 office
IR@oncomethylome.com

Exact Sciences Contact:

Maneesh K. Arora
Chief Financial Officer, Exact Sciences Corp.
608-284-5720

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe Exact's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of Exact's capital resources, expected operating losses, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and expectations concerning Exact's business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of Exact's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC. You are urged to consider those risks and uncertainties in evaluating Exact's forward-looking statements. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, Exact disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in Exact's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.